[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100509102":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":29,"centralContacts":33,"locations":43,"responsibleParty":72,"collaborators":74,"id":77,"slug":29,"hasResults":78,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":29,"eligibilityCriteria":82,"healthyVolunteers":78,"sex":83,"minAge":84,"maxAge":29,"enrollmentInfo":85,"targetDuration":29,"studyType":88,"phases":89,"briefSummary":91,"conditions":92,"keywords":29,"overallStatus":46,"whyStopped":29,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"Northside Hospital, Inc.","OTHER",[8,15,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Moderate Renal Dysfunction","EXPERIMENTAL","Moderate renal dysfunction will receive a 20% dose reduction of fludarabine and no dose reduction for cyclophosphamide.",[13,14],"Drug: Fludarabine","Drug: Cyclophosphamide",{"label":16,"type":10,"description":17,"interventionNames":18},"Severe Renal Dysfunction","Several renal dysfunction will receive a 40% dose reduction of fludarabine and no dose reduction for cyclophosphamide.",[13,14],{"label":20,"type":10,"description":21,"interventionNames":22},"Dialysis Participants","Participants on dialysis will receive a 50% dose reduction of fludarabine and a 25% dose reduction of cyclophosphamide.",[13,14],[24,30],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"DRUG","Fludarabine","Received IV on Days -5 to -3 before CAR T cell therapy",[20,9,16],null,{"type":25,"name":31,"description":27,"armGroupLabels":32,"otherNames":29},"Cyclophosphamide",[20,9,16],[34,39],{"name":35,"role":36,"phone":37,"phoneExt":29,"email":38},"Melhem Solh, MD","CONTACT","404-255-1930","msolh@bmtga.com",{"name":40,"role":36,"phone":41,"phoneExt":29,"email":42},"Caitlin Guzowski, MBA, MHA","404-851-8523","caitlin.guzowski@northside.com",[44],{"facility":45,"status":46,"city":47,"state":48,"zip":49,"country":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Caitlin Guzowski","RECRUITING","Atlanta","Georgia","30342","United States",{"type":52,"coordinates":53},"Point",[54,55],-84.38798,33.749,{"lat":55,"lon":54},[58,59,62,64,66,68,70],{"name":40,"role":36,"phone":41,"phoneExt":29,"email":42},{"name":60,"role":61,"phone":29,"phoneExt":29,"email":29},"H. Kent Holland, MD","SUB_INVESTIGATOR",{"name":63,"role":61,"phone":29,"phoneExt":29,"email":29},"Asad Bashey, MD",{"name":65,"role":61,"phone":29,"phoneExt":29,"email":29},"Lawrence E Morris, MD",{"name":67,"role":61,"phone":29,"phoneExt":29,"email":29},"Scott Solomon, MD",{"name":35,"role":69,"phone":29,"phoneExt":29,"email":29},"PRINCIPAL_INVESTIGATOR",{"name":71,"role":61,"phone":29,"phoneExt":29,"email":29},"Lizamarie Bachier-Rodriguez, MD",{"type":73,"investigatorFullName":29,"investigatorTitle":29,"investigatorAffiliation":29,"oldNameTitle":29,"oldOrganization":29},"SPONSOR",[75],{"name":76,"class":6},"Blood and Marrow Transplant Group of Georgia","100509102",false,"NCT05909059","CAR T-cell Therapy in Patients With Renal Dysfunction","Lymphodepleting Chemotherapy With Fludarabine and Cyclophosphamide Prior to Infusion of CAR T Cell Therapy in Patients With Moderate-Severe Renal Dysfunction","Inclusion Criteria:\n\n* Receiving lymphodepleting chemotherapy prior to commercial CAR-T administration for multiple myeloma, leukemia, or lymphoma\n* Adequate bone marrow function to receive lymphodepleting chemotherapy\n* Renal function \\\u003C\u002F= 60mL\u002Fmin\u002F1.73m2\n* ECOG 0-2\n\nExclusion Criteria:\n\n* Relative CNS disorders\n* Active uncontrolled infection or any other concurrent disease or medical condition that was deemed to interfere with the conduct of the study as judged by the investigator\n* Use of therapeutic dose systemic corticosteroids (defined as \\>20mg\u002Fday prednisone or equivalent) within 72 hours of CAR-T administration","ALL","18 Years",{"count":86,"type":87},20,"ESTIMATED","INTERVENTIONAL",[90],"PHASE2","This is a prospective, descriptive study designed to assess the feasibility of administering CAR T therapy among patients with moderate to severe renal impairment using dose adjusted lymphodepleting chemotherapy.",[93,94,95],"Non-hodgkin Lymphoma,B Cell","Multiple Myeloma","Acute Lymphoblastic Leukemia, Adult","2026-04-15",{"date":98,"type":99},"2026-04-20","ACTUAL",{"date":101,"type":99},"2024-11-18",{"date":103,"type":87},"2027-08-31",{"name":5,"class":6},1]